Q1 2025 Zoetis Inc Earnings Call
Please standby we're about to begin.
Welcome to the first quarter 2025 financial results conference call and webcast for the lettuce.
Steve Frank: Hosting the call today is Steve Frank Vice President of Investor Relations for is it let us.
Steve Frank: The presentation materials and additional financial tables are currently posted on the Investor Relations section of the letters Dot com.
Steve Frank: The presentation slides can be managed by you the viewer and will not be forwarded automatically.
Steve Frank: In addition, a replay of the call will be available approximately two hours. After the conclusion of this call via dial in or the Investor Relations section of the wettest dotcom.
Steve Frank: At this time, all participants have been placed in a listen only mode and the floor will be opened for your questions. Following the presentation.
Steve Frank: If you would like to ask a question at that time. Please press star one on your telephone keypad.
Steve Frank: If at any point. Your question has been answered you may remove yourself from the queue by pressing star two.
Steve Frank: In the interest of time, we ask that you limit yourself to one question and then queue up again with any follow up questions. Your.
Steve Frank: Your line will be muted when you complete your question when posing your question. Please pick up your handset to allow optimal sound quality.
Speaker Change: Lastly, should you require operator assistance. Please press star zero. It is now my pleasure to turn the floor over to Steve Frank Steve You may begin.
Speaker Change: Thank you operator, good morning, everyone and welcome to the <unk> first quarter 2025 earnings call I'm joined today by Kristin Peck, our Chief Executive Officer, and Whitney Joseph Our Chief Financial Officer.
Speaker Change: Before we begin I'll remind you that the slides presented on this call are available on the Investor Relations section of our website and that our remarks. Today will include forward looking statements and that actual results could differ materially from those projections for.
Speaker Change: For a list and description of certain factors that could cause results to differ I refer you to the forward looking statements in today's press release, and our SEC filings, including but not limited to our annual report on Form 10-K and reports on Form 10-Q.
Speaker Change: Our remarks today will also include references to certain financial measures, which were not prepared in accordance with generally accepted accounting principles or U S. GAAP a reconciliation of these non-GAAP financial measures to the most directly comparable U S. GAAP measures is included in the financial tables that accompany our earnings press release and the company's 8-K filing.
Speaker Change: Data today Tuesday may six 2025.
Speaker Change: We also cite operational results, which exclude the impact of foreign exchange with that I will turn the call over to Kristin.
Kristin Peck: Thank you, Steve and welcome everyone to our first quarter 2025 earnings call by staying laser focused on delivering for our customers. Our colleagues drove strong 9% organic operational revenue growth and grew adjusted net income 6% on an organic operational basis, our international segment.
Kristin Peck: Led with 11% organic operational revenue growth, highlighting our global scale and diversification, while the U S grew 6%, excluding the impact of the MFA divestiture.
Kristin Peck: Growth was balanced across species, our innovative companion animal portfolio grew 9% operationally fueled by sustained demand our diverse market leading franchises.
Kristin Peck: Livestock grew 7% on an organic operational basis, driven by broad based double digit performance internationally.
Kristin Peck: Before we go deeper into the quarter I want to briefly address what is top of mind for many of you in today's operating environment. The essential nature of our business remains clear animals provide companionship and nourishment and uncertain times people will rely on bolt.
Kristin Peck: It's precisely because of the enduring secular trends and the fundamentals underpinning our innovation led operating model. This awareness has consistently proven its resilience even through economic turbulence.
Kristin Peck: That resilience is embedded in how we operate from our global footprint and diverse durable portfolio across species and geographies to our omnichannel presence matrix manufacturing network and talented field force.
Kristin Peck: Those dynamics and sure we're operating from a position of strength as we navigate a fluid environment shaped by macroeconomic regulatory and geopolitical uncertainty.
Kristin Peck: We are managing these challenges thoughtfully working to minimize their impact while also seizing opportunities where they exist. So we can continue delivering for our customers colleagues and shareholders.
Kristin Peck: That means executing our strategy with discipline supported by a strong balance sheet operational excellence thoughtful and strategic capital allocation and experienced leadership team ready to adapt as needed. Most importantly, we continued to prioritize what matters most living our purpose and ensuring our products.
Kristin Peck: <unk> reached the people and animals, who depend on them with that context, let's pivot back to the quarter, while our performance reflects the strength of our diverse multi levered strategy I'll touch on a few of the key growth drivers and.
Kristin Peck: In companion animal are combined key franchises grew double digits operationally fueled by exceptional performance in our international segment, where our trusted brands. Even after several years on the market continued to grow by winning new patients and improving compliance with significant runway to further define the standard of care.
Kristin Peck: And deliver meaningful outcomes.
Kristin Peck: Parasiticide are some paragon franchise continues to expand the overall category and is gaining share driven by our Omnichannel strategy meeting customers, where they are whether in the clinic through retail where some <unk> trio is the top selling parasiticide in the U S or via home delivery.
Kristin Peck: As you've heard US say, we are seeing increased conversion to broad spectrum triple combinations setting us up for an even longer term growth tailwind together these dynamics positions us well to continue leading through innovation. Most recently with <unk> U S label expansion to include bleed taper and.
Kristin Peck: <unk>.
Kristin Peck: Similarly key dermatology has consistently been a high growth category built on innovation customer trust and a portfolio that remains the preferred choice for treating allergic etch tool.
Kristin Peck: Through years of investment and strong partnerships, we have built brand loyalty and established a clear leadership position. We continue to leverage our first mover advantage by capitalizing on the breadth of our portfolio to grow and sustained share in a dynamic environment.
Kristin Peck: We remain focused on what we can control execution innovation and customer experience and we are winning with customers every day.
Kristin Peck: Demand for our portfolio remain strong fueled by the convenience and the unmatched flexibility, we provide to that and pet owners through our three differentiated products at.
Kristin Peck: At the same time, an estimated 20 million dogs still untreated or under treated for edge.
Kristin Peck: Advances in diagnostics are helping unlock this opportunity, enabling broader access earlier intervention and better outcomes.
Kristin Peck: That's why we're confident in the enduring strength of this franchise and our ability to continue leading.
Kristin Peck: And similarly building on our track record of scientific innovation, our osteoarthritis pain franchise marks a meaningful advancement in care delivering strong double digit growth and approximately 25 million doses distributed globally, while adoption has been more gradual than initially expected. We are encouraged by the foul.
Kristin Peck: Asian, where lang and the long term potential ahead, we are building and scaling a new category of care when they require significant education and engagement.
Kristin Peck: Both veterinarians and pet owners need time and support to fully understand the safety and efficacy profile of newer more advanced treatments for chronic pain and in this economic environment, We're seeing pet owners take a more measured approach to managing chronic conditions, making choices that reflect broader consumer spending trends, which could include adjustments to <unk>.
Kristin Peck: <unk> or frequency of cure that.
Kristin Peck: That said, we see the impact of these therapies everyday they are safe effective and improving the quality of life for pets, and the people who care for them.
Kristin Peck: To accelerate adoption improve access and grow the OA pain market. We are taking focus strategic actions, we are expanding medical education for veterinarians and partnering with key opinion leaders to shape best practices, we're investing in and plan to leverage post launch studies to generate additional.
Kristin Peck: <unk> real world insights for that.
Kristin Peck: We are engaging directly with pet owners to increase education on the burden of OA pain, and the long term value of treatment and we are launching $3 60 campaigns, including targeted direct to consumer efforts to build awareness and demand.
Kristin Peck: So uptake may be slower in the near term our long term confidence remains strong as we build a durable differentiated market with significant room to grow, especially given the sizable and underpinning underpenetrated opportunity ahead.
Kristin Peck: In livestock, we delivered strong performance with 7% organic operational growth.
Kristin Peck: Two the sale of our MFA portfolio, we consistently reaffirmed our commitment to livestock and our customers because it makes it what if unique and reliable is the diversity and durability of our business model regardless of portfolio mix. One thing is true people need to eat and global demand for animal protein will continue to rise.
Kristin Peck: That's why we continue to invest in solutions that protect the health of food producing animals and safeguard supply chains.
Kristin Peck: Since reporting our results in February we received conditional licensure from the USDA for avian influenza vaccine for chickens, ensuring we are ready to support customers and regulators wherever the pack leaves and addressing this evolving threat.
Kristin Peck: And it's during periods of uncertainty that execution matters. Most our experience enables us to rise to the occasion to stay focused stay ready and continue delivering solutions, where and when they are needed most.
Kristin Peck: As we look to the rest of the year, we're encouraged by our first quarter performance and the steady demand for our products along with the resilience we've consistently seen across the animal health industry. We are maintaining our full year organic operational revenue guidance range of 6% to 8%, reflecting confidence in the differentiation of our portfolio.
Kristin Peck: And our ability to execute in the current environment.
Kristin Peck: While the operating backdrop remains unpredictable. We believe this range appropriately reflects what we know today and we will remain agile and navigating new uncertainties and embracing new opportunities.
Kristin Peck: At the same time based on our current estimates of enacted tariff related cost impacts we are updating our full year organic operational adjusted net income to a range of 5% to 7%.
Kristin Peck: And just to clarify our outlook does not include any potential impact from future tariffs as it's still too early to know how the situation will unfold.
Kristin Peck: And with that I will close with this the performance we share today reflects the dedication of our colleagues around the world living our purpose being a trusted solutions provider to our customers and delivering results through their relentless focus.
Kristin Peck: Uncertainty is top of mind for everyone, but it's not unique to the wettest what sets us apart is how we respond.
Kristin Peck: <unk> has consistently leveraged its innovation led customer first operating model to outperform the market and deliver value for both customers and shareholders. We remain vigilant and agile will draw on our experience navigating complexity stay clear eyed in our decision, making and continue moving forward with discipline.
Speaker Change: We are confident in the strength of our portfolio in the promise of our pipeline and our ability to adapt most of all we're confident in the commitment of our teams around the world to lead through change and continue delivering for our customers and shareholders because ultimately what we do matters for the well being of animals.
Speaker Change: People and communities, that's why animal health is both essential and resilience and industry fueled by long term demand and rising expectations for high quality care.
Speaker Change: And as a global leader, we recognize our responsibility to lead today and well into the future with that I'll turn it over to Whitney to walk us through the more detailed financials, let me.
Whitney Joseph: Thank you Kristen.
Whitney Joseph: In the first quarter, driven by balanced portfolio growth, we posted $2 $2 billion in revenue growing 1% on a reported basis and 9% on an organic operational basis, which excludes the impact of foreign exchange and the MSA divestiture.
Whitney Joseph: Our organic operational growth was driven by 4% price and 5% volume.
Whitney Joseph: Adjusted net income of $662 million grew 4% on a reported basis and 6% organic operational basis.
Whitney Joseph: Our companion animal portfolio led the way with $1 $5 billion in revenue growing 9% operationally.
Whitney Joseph: Globally and on an operational basis, or some Parker franchise contributed $367 million growing 19% Q dermatology posted $387 million growing 10%.
Whitney Joseph: And our oil <unk> reported $147 million growing 15% in the quarter.
Whitney Joseph: Our lifestyle portfolio also contributed organic operational growth of 7% on $645 million in revenue.
Whitney Joseph: Now moving onto our Q1 segment results.
Whitney Joseph: U S revenue grew 2% on a reported basis and 6% on an organic operational basis in the quarter with companion animal growing 8% and livestock declining 2% on an organic operational basis.
Whitney Joseph: In companion animal U S growth was driven by our three key franchises, while vaccines faced headwinds from supply timing coupled with competitor reentry.
Whitney Joseph: Across the portfolio alternative channel sales continue to outpace the vet channel offering greater convenience, where pet owners, improving compliance and stickiness.
Driven by strong growth in auto ship programs that boost compliance and increase the lifetime value of each dog on treatment of empirical franchise posted 17% U S growth this quarter on $260 million in revenue.
Whitney Joseph: Additional competitive entrants are accelerating the market shift to triple combinations, where we continued to gain share. Thanks to the strength of our field force, our first mover advantage and ongoing innovation, including expanded label claims.
Whitney Joseph: And key dermatology sales were $249 million.
Whitney Joseph: Of 7% with growth across both Abigail inside a point, while also reflecting the comparison to last year's initial distribution stocking of agricultural.
Whitney Joseph: Africa growth continues to be driven by the retail channel and continued conversion to the trouble, which is easier to administer and promote David compliance.
Whitney Joseph: Our OA pain maps, the <unk> posted a combined $65 million in USL growing 14%.
Whitney Joseph: <unk> grew 17% on $47 million in revenue and celestia posted $80 million in revenue growing 7%.
Whitney Joseph: To reiterate <unk> point building, a new category of care. It takes time, but we remain confident in this sizable market potential.
Whitney Joseph: Our foundation is solid.
Speaker Change: And record penetration confirms that veterinarians when better OE solutions.
Speaker Change: Organic operational declines of 2% and livestock are primarily driven by declines in Jackson, just to aggressive price competition and the timing of price adjustments in the prior year as well as the timing of supply of soft tissue.
Speaker Change: Moving onto our international segment revenue was flat on a reported basis and grew 11% on an organic operational basis.
Speaker Change: Companion animal grew 10% operationally and livestock with 12% on an organic operational basis.
Speaker Change: Similar to the U S International Companion animal sales were driven by strong performance in Austin breaker key dermatology and OA pain franchises.
Speaker Change: Our international <unk> franchise, including some <unk> and some perenco true with 23% operationally on $106 million in sales with both brands driving strong market share gains.
Speaker Change: <unk> grew 22% operationally on $61 million in sales driven by expansion of the combination parasiticide market, especially in Latin America and Eastern Europe.
Speaker Change: Compared to a true up contributed $46 million.
Speaker Change: Growing 26% operationally with strong performance across all regions.
Speaker Change: All key dermatology franchise delivered $138 million in revenue or 15% operationally with double digit growth in both App Aquila inside a point.
Speaker Change: Our performance was driven by field force engagement with vets, leading to new patient starts and improved compliance, especially among chronic cases.
Speaker Change: As Christian highlighted we're executing globally on our key strategic priorities. We continue to show strong progress driven by continued conversion of <unk>, which now accounts for 57% of doses in Europe.
Speaker Change: Internationally, our <unk> grew 16% operationally pushing $82 million in combined revenue.
Speaker Change: International sales of Isabella were $65 million growing 14% operational.
Speaker Change: Our international efforts have had a significant head start over the U S. As we enter our fifth year in some markets.
Speaker Change: We continue to drive double digit sales growth and expand both the market and our share.
Speaker Change: So last year sales were $82 million growing 27% operationally in the quarter.
Speaker Change: So let's see now holds over half of the <unk> market share in international markets underscoring the strong demand for employee solution for cats.
Speaker Change: International livestock grew 12% on an organic operational basis in the quarter.
Speaker Change: Growth was driven by higher price, including some impacts from high inflationary markets.
Speaker Change: Volume growth, excluding the impact of Mfa's was driven by poultry vaccine growth from key account penetration across Asia, the middle East and Latin America.
Speaker Change: Caddo contributed to growth with a return to a more normal environment in Australia as well as strong demand across much of South America, Canada and Mexico.
Speaker Change: Our fish business saw good vaccine growth across geographies.
Speaker Change: Now moving onto the P&L for the quarter adjust.
Speaker Change: Adjusted gross margin of 72, 1% grew 140 basis points on a reported basis.
Speaker Change: Foreign exchange had a favorable impact of 220 basis points.
Speaker Change: Excluding FX, we saw lower margins due to higher manufacturing costs in line with our expectations and included in our initial guidance in February which should improve as we worked through inventory value that prior year standards and unfavorable product mix.
Speaker Change: This was partially offset by the favorable impact of our MFA divestiture.
Speaker Change: Adjusted operating expenses increased 3% operational.
Speaker Change: Growth was driven primarily by SG&A increases of 4% operationally, mainly due to higher compensation related expenses and increased direct to consumer advertising.
Speaker Change: R&D declined 2% operationally this quarter due to lower project spend primarily due to timing.
Speaker Change: Adjusted net income grew 2% operationally and 6% on an organic operational basis.
Speaker Change: Adjusted diluted EPS grew 4% operationally in the quarter and 8% on an organic operational basis, 2% higher than adjusted net income and reflective of a lower share count as a result of our ongoing share buybacks.
Speaker Change: Before we get into guidance I will expand on the business impact of the tariff landscape.
Speaker Change: While the current situation remains fluid, we are well positioned to navigate this dynamic environment.
Speaker Change: We'll be thoughtful and deliberate in our actions with a clear focus on both near and long term goals.
Speaker Change: We will leverage the diversity of our revenue across geographies and species to seize opportunities for growth.
Speaker Change: Ensure we work to control expenses Braxton physically and manage inventory.
Speaker Change: People and animals depend on our products and we will continue to deliver for customers.
Speaker Change: Now moving to guidance for the full year of 2025, which reflects continued confidence in our operating model, while acknowledging that there will be some profitability impact in the near term due to enacted tariffs.
Speaker Change: Please note that guidance reflects one exchange rates as of late April.
Speaker Change: For the year.
Speaker Change: <unk> revenue between $9 45, and $9 575 billion.
Speaker Change: With increases due to favorable foreign exchange when compared to the late January rates used in our initial February guidance and maintaining organic operational growth of 6% to 8%.
Speaker Change: We recognize that there are external factors that are beyond our control as such our current guidance does not include any assumed impact of future tariffs policy changes or further worsening of the macro environment.
Speaker Change: We continue to expect broad based operational growth across our <unk> key dermatology and OA pain franchises and reiterate our expectation that these combined innovative franchises will grow double digits in 2025.
Speaker Change: We now expect adjusted net income to be in the range of $2 775 to $2 82 5 billion.
Speaker Change: Reflecting the operational growth of 5% to 7% on an organic operational basis.
Speaker Change: Our revised adjusted net income guidance is reflective of the estimated impact of current enacted tariffs, while not accounting for any future changes in the tariff landscape.
Speaker Change: Lastly, we expect adjusted diluted EPS to be in the range of $6 20.
Speaker Change: To $6 30.
Speaker Change: And reported diluted EPS to be in the range of $5 85.
Speaker Change: To $5 95.
Speaker Change: This EPS increase is primarily due to favorable foreign exchange compared to the lead generators as well as the reduction in our share count due to share repurchases in the quarter slightly offset by enacted tariffs.
Speaker Change: As we indicated in February our EPS projections are based on current share counts and do not consider the future favorable impact of our ongoing share repurchase program.
Speaker Change: As we look forward to the remainder of the year. We recognize there is a degree influenced uncertainty, but we remain confident in our outlook.
Speaker Change: In the past our proven diversified model has delivered steady predictable and meaningful growth through dynamic environments.
Speaker Change: Lead into attractive end markets with strong fundamentals.
Speaker Change: Our portfolio of market, leading franchises, a sustainable stream of innovation and a proven track record of execution.
Speaker Change: Now I'll hand things over to the operator to open the line for your questions operator.
Speaker Change: Thank you, ladies and gentlemen, if you would like to ask a question at this time. Please press star one on your telephone keypad. If at any point. Your question has been answered you may remove yourself from the queue by pressing star two.
Speaker Change: In the interest of time, we ask that you limit yourself to one question and then queue up again with any follow ups. Your line will be muted. When you complete. Your question. We also ask that when you pose your question. Please pickup your handset to allow for optimal sound quality.
Speaker Change: We'll hear first from Erin Wright with Morgan Stanley. Please go ahead.
Speaker Change: Great. Thanks.
Speaker Change: So first on.
Speaker Change: I'll do my Grella first and then Tara.
Speaker Change: I guess can you speak to what you're seeing across the U S market in terms of them by Grella labor held back a response relative to your expectations, there and how do you think.
Speaker Change: The longer Athene OA pain product.
Speaker Change: Could potentially replace our NTN sorted the OA pain offering.
Speaker Change: We had in Q potentially next year and then on para.
Speaker Change: Can you describe what exactly is embedded in terms of the gross tariff impact and what mitigation efforts you have and then and then what does it mean when you say enacted tariffs I guess what character jurisdictions are you incorporating our.
Speaker Change: Our product category, where do you have I guess, the most exposure in and what is the tariff impact now embedded in guidance. Thanks.
Speaker Change: Sure. Thanks, Erinn I will take the libretto question I'll, let <unk> take the tariff question when I'm done.
Speaker Change: And you sort of mentioned in his prepared remarks, we had about 15% organic operating growth and labella across the globe with them in the U S having about 17%.
Speaker Change: We're continuing to grow the market and that satisfaction remained strong our focus right now is on building and scaling the new category of care and really focusing on continued education and engagement now that the label.
Speaker Change: We're really focusing on expanding our medical education.
Speaker Change: We're investing in a number of post launch studies as we've talked about to generate more real world data.
Speaker Change: We're also bringing in some key opinion leaders from Europe, who had the product for over five years to share their experiences in the U S as well as investing in targeted DTC. So we continue to have long term confidence it remains strong.
Speaker Change: We really think labella is meeting a significant unmet medical need and remain excited what do you want to cover the tariff question sure.
Speaker Change: Our guidance today reflects the net impact of the tariffs that are actually already in place.
Speaker Change: So that's net of any mitigation that we have already.
Speaker Change: Put together here, although this situation remains fluid to give you a little bit more color in terms of where the exposure is and what we have reflected today. This is primarily from imports related to <unk>.
Speaker Change: So a few of our lifestyle products.
Speaker Change: <unk> from China, and then some impact from.
Speaker Change: A few of our diagnostics products as well as certain veterinary accessories.
Speaker Change: Zooming out.
Speaker Change: The situation remains fluid honestly, and we continue to monitor as well as our actively planning various scenarios, depending on where tariffs land keep in mind, we have.
Speaker Change: Broad diversity of our geographic footprint in 60% of our manufacturing footprint is actually in the U S.
Speaker Change: Export more out of the U S and we import into the U S and particularly when you think about companion animal vast majority of our sales are actually produced in the U S. So those and good.
Speaker Change: A good portion of the companion animal sales outside the U S actually produced in the U S and so I think when you think about that our exposure is really.
Speaker Change: Likely more from retaliatory tariffs from other jurisdictions. So most of our exports go to Europe as well as our imports are actually coming from Europe. So you think about that in the context and of course, we continue to monitor those given our supply chain as broad as it is that gives us lots of mitigation opportunities. So we until we know exactly what where tariffs.
Speaker Change: Land, we won't know exactly how much we will mitigate but we do feel confident that our footprint allows us quite a bit of flexibility to do that those will range in terms of timeframe, where they can be executed.
Speaker Change: From immediate where may be moving inventories all the way to longer term in terms of what does that mean in terms of our footprint. So lots of opportunities for us as we look at that but given our diversity from a geography product et cetera standpoint, we feel we are as well positioned.
Speaker Change: To navigate this as anyone else.
Michael: We'll hear next from Michael <unk> with Bank of America. Please go ahead.
Michael: Great. Thanks for taking question guys I'll start on the competitive.
Michael: <unk> side of things I think what Neil Christian you guys, both called out competitive entrants a little bit more in your prepared remarks, obviously, you've got that nexstar plus in the market for a while now and also Corneliu cuatro and that's it.
Michael: <unk>.
Michael: Just if you could dive into a little bit more of like where are you seeing the most competitive pressure how is it taking shape is it more in terms of price.
Michael: And even you are seeing in terms of pre stocking pre selling.
Michael: Theres a derm competitor expected later this year as well so just sort of what have you seen so far what are you factoring into your guide.
Michael: From the competitive side of things in those categories and then a follow up on <unk>.
Michael: On the Aaron's question there.
Michael: I just want to.
Michael: Now that you've had the label change and some of the learnings from the last couple of months is your assumption for fiscal year 'twenty five library it any different than it was before do you think you'll be able to offset some of these as you go through the year just wondering if.
Michael: If your thoughts on the ramp for this year any different than they might have been three months ago. Thanks.
Whitney Joseph: Okay, Great I'll start in on the competitive side and then let at Whitney build off of it I mean, I think what's really important to note in both dermatology and parasiticide as we were the first mover and I think that's really important because especially if you look at parasiticide being the first mover made a big difference really we've just been growing our share over time as we talked about.
Whitney Joseph: We obviously had one of the biggest competitors enter over a year ago, and we're printing 19% growth overall for.
Whitney Joseph: For the quarter and trail. So I think that's incredibly strong I think what we're really seeing is that there's still 40% growth in our combined flea tick heartworm space and the more people that enter into more.
Whitney Joseph: People get switched into combo therapies from single therapies or topical or collar. So we continue to see that.
Whitney Joseph: Regardless of who is entering we have an excellent product. It's continued to compete really well in the market. We're really proud of the execution on this in the U S and around the globe. So we've seen competition.
Whitney Joseph: We're obviously going to continue to see more competition I think what's also suddenly to focus on is that right now we have a 40% share and puppies.
Whitney Joseph: Obviously once one goes on a product it is rare that it'll switches to I think thats, a really good indication of where that's going in the future.
Whitney Joseph: As we talked about we are expecting potentially a new competitor in dermatology, what you can get into the specific that's baked in but again I'd say if you look at dermatology, we have three excellent products that have been in the market for a long time that are accepted that.
Whitney Joseph: And over 90% satisfaction rate with those products and we are the first mover. So although when you talk about what that means and guidance et cetera on that if you want to follow up anything else on the broiler. If you want <unk> sure. If you look across our three key franchises and I think this will crossover both for your first question on competitive entrants as well as your question on Labella and I'll double click on that a little bit.
Whitney Joseph: So first of all our large three key franchises, we expect to grow double digits in 2025 they.
Whitney Joseph: They delivered 14% in the first quarter and remain double digit and our guidance.
Whitney Joseph: I think if you look at these areas, including those that already have competition of where we expected we expect more entrants to come in the bigger picture is the opportunity that remains I think in every area you have large markets even at the current sizes in derm, we still have $20 million or under treated or untreated and clearly with them.
Whitney Joseph: The digit growth in that category.
Whitney Joseph: Decade, plus later, we are accessing.
Whitney Joseph: Those expansion opportunities and we have more to go, particularly when you think about international.
Whitney Joseph: If you look at La Grella again, I'll keep franchises are double digit expectations for the year, we haven't given specific guidance.
Whitney Joseph: Insistently with the first guidance in February on a particular product, but I think I will share this.
Whitney Joseph: We had a very strong launch to this product in terms of.
Whitney Joseph: Penetration in clinics in the U S et cetera, if you look at that that's a strong foundation for us and really if you look at the feedback from vets. They remain very strong in terms of satisfaction and so with 27 million Medicalized dogs in the U S alone.
Whitney Joseph: With full way and only 9 million being treated $8 million on nsaids and $1 million on the <unk> I don't think I need to spill I'll, just how vast the opportunity is and we're still early and clearly as the adoption curve is slower than we expected as we said in the prepared commentary.
Whitney Joseph: We are doubling down on efforts to drive education and awareness et cetera.
Whitney Joseph: The industry has seen this before with other products and we've seen this before and we're confident in terms of the long term opportunity here and our position in it as a first mover in the impacts of making all dogs across the world. So we'll continue to drive those yes, and the other thing I'd say is we're really seeing this as you know.
A huge market opportunity of the future we've talked for a while that we think the overall market opportunity for <unk> is between two and $3 billion.
Whitney Joseph: And we are investing as you know in a long acting OE monoclonal antibody that as we mentioned earlier in the year. We are expecting approval for this year. This would be a long acting three month injection. It is a new and different antibody.
Whitney Joseph: Labella with a unique binding site and we're expecting the dosing range to be about 10 times lower than labella. So.
Whitney Joseph: We have a lot of confidence in continuing to grow this market and the potential for this market given all the things that when he said and we'll continue to invest in lifecycle innovation behind labella as well.
Speaker Change: We will hear next from Jon Block with Stifel. Please go ahead.
Jon Block: Great. Thanks, guys. Good morning Hope you can hear me, Okay, and maybe just building on a couple of the prior questions. Let me just pretty straightforward, but can you just maybe help us in bridges to the 20% increase.
Jon Block: The 2025, EPS guidance, because obviously back of the envelope, but even with the advantageous move in FX, the lower interest expense and the lower shares I'm actually having a hard time getting into 2000, and that's arguably before any tariff headwind I don't know if you can give us a gross.
Jon Block: Net tariff impact.
Speaker Change: Outside of the equation and then Chris I guess, just a little bit more on Libra.
Speaker Change: A pretty direct question do we assume or should we assume flat U S. <unk> revenue for the next two to three quarters until the long acting is out there I think the targets here in 'twenty five give or take and is there anything call. It in the near term to Reaccelerate. The U S Library revenues before the long acting and then I know you.
Speaker Change: You just gave some helpful information on the long acting is that going to carry call. It a different brand versus libra. Thanks, guys.
Speaker Change: Yes, sure John I'll take the bridge to the EPS raise in dollars of for you.
Speaker Change: If you go back to our initial guidance in February which use rates from late January versus where rates are as of late April we.
Speaker Change: We are seeing initially.
Speaker Change: Our guidance was about a $200 million headwind related to FX on a reported basis and that was really reflective of the dollar has strengthened particularly in the second half of 2024. If you look at where rates are at the end of April largely driven two thirds of this change is driven by the euro the pound Sterling and the yen.
Speaker Change: We're looking at most of that not all of it nearly all of it actually.
Speaker Change: Being reversed with the weakening dollar so that is largely if not entirely was driving the EPS.
Speaker Change: The change that you see from us driven by FX and I would tie. This also with trade policy and tariffs and so on so we talk a lot about the impact that has on the organic operational but it does have somewhat of the opposite effect in terms of what is going to the dollar and a demand for that so I do want to make sure that that is at least looked at and recognized.
Speaker Change: And so.
Speaker Change: The impact just easier now in terms of tariffs net of mitigation, but we're calling about $20 million.
Speaker Change: Headwinds that were put in here and keep in mind in February we said, we did not reflect Harrison who would do so as we know more and based on was enacted.
Speaker Change: That reflected here today, but for that our organic operational growth in adjusted net income will be the same as it was in February.
Speaker Change: Again, giving you a little bit more color in terms of what that impact is and I gave you. Some more in terms of how we're positioned as we continue to monitor the situation and where we have mitigation opportunities. As we look ahead hopefully that help in terms of the FX I do think what you're going to see is it's slightly.
Speaker Change: Slightly near flat for the year now with headwinds in the first half and tailwind in the second half based on where rates are again, we don't forecast the rates were simply using the spot rates late April and assume they stay where they are which we know they won't this would be the impact.
Speaker Change: So that is consistently how we have reflected on ethics.
Speaker Change: A follow up on your question with regards to Labella I mean, as you know, we obviously don't give quarterly guidance, but as I mentioned earlier, we are obviously investing to continue to grow and scale. This product throughout the year. We're doing all the things. We mentioned you know obviously the medical education. The DTC. We're obviously investing in many post launch studies to generate real world data on <unk>.
Speaker Change: A few of those come out right now we provided our pharmacovigilance data to Frontier's Journal, which indicated that all individual events are both rare and very rare.
Speaker Change: We also did a libretto meloxicam, which had 17 aes for Meloxicam in Forfar Labella, we're continuing to invest in additional real world studies to support the brand. So we are investing obviously to grow. This brand we are not waiting for growth until we get a long acting monoclonal antibody and I think you also said it will obviously have a different brand. It is a unique.
Speaker Change: Antibody until obviously, therefore cannot share the blend of labella I get and it's a unique molecule. So that would not have the same branding, but look we can do I. Just wanted to reiterate this is a $2 billion to $3 billion market. We are only $1 million right now on the product. There is 9 million are treated in the United States, but I'd argue by the way there's 2002.
Speaker Change: $7 million with OE, so beyond even what's treated today theres, an untreated market as well so as you look at that so we see this as a significant opportunity that we're going to continue to invest behind.
Speaker Change: We'll take our next question from David Watson Berg with Piper Sandler. Please go ahead.
Speaker Change: Alright, Thanks, I'm going to actually get away from the library of my question.
Speaker Change: So Amazon is now selling some of the online drug it's probably I think it is just singles right now, but maybe get a broad backdrop can you talk about any changes in your.
Speaker Change: Sales of our.
Speaker Change: Sales and marketing efforts both in terms of educating that were direct.
Speaker Change: Direct to consumer strategies, and with Amazon do you see an acceleration of trends to the alternative channel or do you think this is just maybe more market share taking and it would just see the same exact acceleration are the same exact.
Speaker Change: Trends, we've seen and then just a really quick one on the FDA and particularly the CMV can.
Speaker Change: Can you can you tell whether or not there is any any potential backlogs are delayed in the FDA I know that the actual reviewers there hasnt been any cuts in order to that but I mean, I think there would be some maybe in some of the support staff that might have like maybe a downstream effect, but thank you shar.
Speaker Change: I'll start with your second question first yes, we are obviously monitoring any changes to both FDA and USDA are closely they're obviously workouts already at FDA, but we have not seen any slowdowns on any of our pipeline products as we talked about we have a very robust pipeline. We work very closely with the FDA and look we're working very closely.
Speaker Change: With the administration with Congress and with the regulators to help shape that evolving environment, we're looking for opportunities to support their efforts on efficiencies, while supporting innovation, we think there's lots of opportunities to speed innovation and if there's been a lot of time in D. C. Working with them. We really think that innovation is critical as you think about the food supply chain is.
Speaker Change: Well as public health as.
Speaker Change: As well as really bringing unmet products to market. So it's a real focus of ours, but we have not seen any slowdown in any of our pipeline products currently at the FDA or the USDA, but we're spending a lot of time, there, making sure we continue to shape this environment.
Speaker Change: Second question was on retail growth I'll start there and see what when he has got to build on it first I would underscore that retail in the quarter grew 40% that was obviously, there's a little bit there on some one time stocking. So when you can get into that but right now retail is 21% of our U S business and this has been growing every year. So I mean I think.
Speaker Change: Amazon just one more but why do you want to get into some of the specifics there, yes, I'd be happy to I think to your point. If you look at retail and when we talk about alternative channels, we have both retail and home delivery, which we're seeing traction there as well if you look at our retail.
Speaker Change: In the quarter about 40% growth some of that as we talked about in February we saw a little bit of inventory decrease at the end of December through the holiday season, some of that pick back up in January so a little bit of crossing over.
Speaker Change: But overall the trend line continues in terms of the strength that we've seen there when I assume al and I think we talk a lot about diversification in this company right. We're talking about product categories geographies species et cetera, I do think alternative channels.
Speaker Change: Also presents another level of diversification, we are certainly positioned well to meet the consumer wherever their channel of choice is and that includes in the clinic and when products move from the clinic to these alternative channels, we're positioned to capitalize on those as well. So I think any move by any party, whether Amazon or anyone else is going to come.
Speaker Change: To give more choices to the consumer and our products are available to them to be to drive that and I think from an economics perspective, we've talked about on this call before they are neutral to positive versus the overall. So this is another area that we are well positioned to continue to capitalize on in terms of where our bodies and I think that will also continue to grow the compliance for.
Speaker Change: Most of our key products and we've got significant percentage of our sales currently for both <unk> and <unk> trio.
Speaker Change: 40% of both in the retail channel. So I think Amazon is just one more entrants there.
Speaker Change: Well hear next from Brandon Basquez with William Blair. Please go ahead.
Brandon Basquez: Hey, everyone. Thanks for taking the question Christian you made a comment about on the library side that maybe consumer sentiment or consumer spending is weighing a little bit.
Brandon Basquez: Maybe on compliance can you just talk a little bit about what you guys are seeing through April given kind of consumer sentiments rolling over a little bit not just in <unk>, but just the broader portfolio or are you seeing meaningful changes in compliance across the board or not and just kind of the feeling is were going through the second quarter and then one quick modeling follow up question, but can you.
Brandon Basquez: Just talk about what price and mix price and volume expectations are for the rest of the year as well. Thanks.
Speaker Change: Sure, Yes, I think what we talked about in our prepared remarks is obviously adoption has been more gradual as you look at sort of the OA pain market and honestly some of the more expensive chronic medications right now than we probably initially expected, but look we're really encouraged by the foundation that we're building we are starting to see.
Brandon Basquez: In small pockets of more measured approach to managing chronic conditions.
Brandon Basquez: I think consumers are making choices that reflect sort of broader consumer consumer trends, but I think what's great about our portfolio is how broad it is across so many different categories. So maybe that is the most expensive. We also you know you can look at it you know in <unk>.
Brandon Basquez: Looking at the dark space and we're continuing to see incredibly strong growth right now in wellness. So as we always say, we see the animal health industry as incredibly durable and recession resistant obviously, we're not recession proof.
Brandon Basquez: And I think what really sets <unk> apart in this is that we're more resilient than the industry given the innovation that we bring to market we have really disruptive.
Brandon Basquez: Products that meet unmet medical needs.
Brandon Basquez: And as you look at a growing global population, whether that's on the food side or in the companion animal side I think what it has always whether these are better than others and we believe we'll continue to do so when do you want to take the second question sure look our price and volume mix is consistent with how we saw them coming into the year and I'll remind you of a few points here in 2024.
Brandon Basquez: We saw strong volume growth, particularly across our key franchises, even as we saw price elevated.
Brandon Basquez: Elevated the last couple of years to the tune of 5% to 6%. We came into this year, saying, we expect price to be above our historical two to three but below those levels from the last couple of years and you saw that play out in the first quarter.
Brandon Basquez: Our volume growth out of the 9% organic operational growth was 5% volume.
Brandon Basquez: 4% price I would say the direction of travel for the rest of the year would be consistent in terms of that mix and one last note as last year, we saw higher contributions from our Hyperinflationary markets, particularly when you think about livestock and international.
Brandon Basquez: Where we're seeing much less of that though we're seeing some in the first half and the first quarter here much less of that this year versus what we saw last year.
Chris Schott: We'll turn now to Chris Schott with Jpmorgan. Please go ahead.
Chris Schott: Okay, great. Thanks, so much for the questions.
Chris Schott: Maybe just starting off on <unk> can you just remind us of your latest expectations for merck's entrance into the market whats kind of reflected in guidance on that and maybe bigger picture on <unk>.
Chris Schott: What percent of the market is <unk> at this point and how important is that I guess in terms of kind of protecting the franchise competitively. My second question, obviously, a very solid start to the year I know you don't give quarterly guidance, but just anything notable we should be watching in terms of quarterly gating as we think about the rest of the year from here. Thanks, So much.
Chris Schott: Sure I'll take I'll take this and see if Chris.
Chris Schott: Chris I wanted to add to it. So when you look at our guidance today consistent with February we put a number of scenarios around the timing of competitive entrants.
Chris Schott: Well as any short term.
Chris Schott: Our promotional activities that they may have this does not take away from our long term view in terms of the opportunity to continue to expand these markets and are confident that we will continue to drive growth in those particularly given our first mover advantage. So I want to make sure that is really well understood that our that our consideration is more short term implications around promotions and not.
Chris Schott: Long term confidence that we continue to have in those on Apple, particularly just a chewable conversion. If you look at the U S and we exited the first quarter around 31% in the aggregate a little bit higher.
Speaker Change: And the vet clinics.
Speaker Change: So forth if you look at international we're seeing about 50% conversion across international but in Europe, It's actually about 57%. So we're continuing to see that climb in terms of our position and last thing I'll say is coming into a year ago with the launch of <unk>, We would have anticipated as we said before.
Speaker Change: Higher conversion of true, but I think it's the stickiness of Apple, particularly when you think about the satisfaction levels amongst vets and pet owners auto ship et cetera that is actually driving the conversion rate to be lower than we would have said and I think that's a good signal for us as we compare prepare for competition and then of course longer term because of expanding the market.
Speaker Change: We will go now didn't have anti with BNP Paribas. Please go ahead.
Speaker Change: Hi, Thanks for taking my question.
Speaker Change: One on Libra.
Speaker Change: I'd like to pivot back to accessing the moderate population in the U S. At some point.
Speaker Change: And a follow up on the FDA did you expect the FTE head count reduction to impact you.
Speaker Change: Timeline.
Speaker Change: And then finally can you discuss a new fleet.
Speaker Change: Type one indication.
Speaker Change: Okay.
Speaker Change: Uh huh.
Speaker Change: Credit your question. Thank you.
Speaker Change: Sure I'll start with your last one yes, we did get approval for the prevention of taper them. As we've said before this is we didn't see that is critical.
Speaker Change: Critically important.
Speaker Change: We've mentioned this previously on this is just a nice incremental on it certainly makes it very little differentiation between us and others, but we as we said before we don't see this as a major driver. We didn't think it was a major issue.
Speaker Change: Before.
Speaker Change: With regards to your question on the <unk> and the shift to moderate patients. That's obviously a key part of our focus right now and is consistent with all the different levers that we're really focused on right now on making sure we expand medical education, bringing in the international Kols et cetera is moving into that and your last question was on the FDA and the <unk>.
Speaker Change: Packed on either competitors or a long acting as I said, we have not experienced any delays at the FDA and we would think others would share the same view at this point I, obviously can't speak for them.
Speaker Change: So we're not expecting any issues with the FDA at the moment based on what we know today to be slowing down ours or anyone else's pipeline.
Speaker Change: Okay.
Speaker Change: We'll go next to Steve Scala with TD Cowen. Please go ahead.
Speaker Change: Hi, Good morning. This is Chris on for Steve. Thanks for taking my question two just on tariffs post it seems like the Trump administration's pursuing pharmaceutical tariffs under section 232 National Security claims based on your interactions with Washington of animal health products critical to U S National security and what's the likelihood that U S pet products could be <unk>.
Speaker Change: <unk> from.
Speaker Change: Some blood receptor tennis, thank you.
Speaker Change: Sure.
Speaker Change: Our team here in at me personally I've spent a lot of time in D. C. On the issue of the 232 sectoral tariffs on pharmaceuticals.
Speaker Change: What we've advocated for and have had a great audience for us what theyre trying to solve is not the problem that we see in animal health is certainly not a problem I actually said you know if you want to be the poster child I think the wettest is it 60% of our total manufacturing is in the United States, 75% of what we sell in the United States, We make in the United States and we are in.
Speaker Change: At quarter, so in the sense of their desire for security and pharmaceuticals in the United States I don't really think that animal health or is that what is the challenge.
Speaker Change: We've shared this point of view with a number of people I think it's too early to tell which is why we were quite clear in.
Speaker Change: In the guidance that this obviously only included currently enacted tariffs I would definitely not want to presume where the where they will ultimately come out on it but I think we have a very strong argument and we've been spending a lot of time, making sure. They understand the differences between animal health and human health and where our manufacturing is importantly, we've made the case of where our intellectual property.
Speaker Change: Which is also in the United States and where the vast majority of our R&D dollars are which are also in the United States. So I think we've had a good audience, but I wouldnt presume to predict what the administration will this year.
Daniel Clark: We'll turn now to Daniel Clark with Leerink Partners. Please go ahead.
Daniel Clark: Great. Thank you just another question on on Labella, you know what when you think about how the launch has progressed versus your initial expectations is it really on the patients start side or on the months on therapy side that you've seen like a bigger divergence from where you thought performance is going to be.
Daniel Clark: That's my question. Thank you.
Daniel Clark: So look I think if you look at the performance of Labella first of all just to see just how much interest. There is in terms of looking for solutions for your pain, you saw 86% penetration of our clinics and we continue to see very strong satisfaction levels.
Daniel Clark: <unk>, who are using the product. So I think that really is a great foundation for us we've seen a transition into more moderate cases in patient starts and expansion of the market with those that were previously not treated by nsaids in Europe and that continues to be our focus in the U S through education of veterinarians and pet owners in terms of the long term impacts of OA pain.
Daniel Clark: Over time, which I think are important to note and we will continue to drive to drive those so as we said the uptake hasn't been as fast on the ramp as you'd like but I think the foundation is strong and certainly undoubtedly the size of the opportunity remains very fast.
Daniel Clark: As there are no further questions at this time I would like to turn the floor back over to management for any additional or closing comments.
Speaker Change: Thank you as always I want to thank everyone for joining today for your questions and importantly for your continued interest in <unk>.
Speaker Change: Just to summarize we have the industry's most diverse and durable portfolio and animal health is essential and both the industry and <unk> have proven to be resilient across many different economic cycles, and all different types of market conditions and that's why we continue to see steady sustainable demand for our products across species and geographies.
Speaker Change: Graffiti and as we look ahead, we remain focused on executing our strategy with discipline, while staying agile and responsive to the dynamic world around us.
Speaker Change: Strongly believe that with our innovation, our global reach and our dedicated teams. We are confident in our ability to continue to lead this industry board.
Speaker Change: Everyone for joining us and have a great day.
Speaker Change: Thank you once again, ladies and gentlemen that will conclude today's the latest event. Thank you for your participation. You may disconnect at this time and have a wonderful rest of your day.
Speaker Change: Yeah.
Speaker Change: Hum.